Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052894 | 1.00 | FUCA1 (0.40) | FUCA1TACR1GBA1SIRT1GAA | |
| SCHEMBL6052770 | 1.00 | FUCA1 (0.40) | FUCA1TACR1GBA1SIRT1GAA | |
| SCHEMBL6052774 | 1.00 | FUCA1 (0.40) | FUCA1TACR1GBA1SIRT1GAA | |
| SCHEMBL6052771 | 1.00 | FUCA1 (0.40) | FUCA1TACR1GBA1SIRT1GAA | |
| SCHEMBL3094922 | 0.92 | TACR1 (0.38) | FUCA1TACR1SIRT1GAAMAPK1 | |
| SCHEMBL6704820 | 0.92 | TACR1 (0.38) | FUCA1TACR1SIRT1GAAMAPK1 | |
| SCHEMBL4086816 | 0.82 | TACR1 (0.44) | TACR1GBA1GAACYP2C19SMN1; SMN2 | |
| SCHEMBL6052746 | 0.82 | TACR1 (0.44) | TACR1GBA1GAACYP2C19SMN1; SMN2 | |
| SCHEMBL4095230 | 0.82 | TACR1 (0.44) | TACR1GBA1GAACYP2C19SMN1; SMN2 | |
| SCHEMBL6052769 | 0.80 | TACR1 (0.38) | FUCA1TACR1GBA1SIRT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | FUCA1 1960/4885TACR1 3420/4885GBA1 729/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | FUCA1 1960/4885TACR1 3420/4885GBA1 729/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | FUCA1 1960/4885TACR1 3420/4885GBA1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.